{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 105,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Uses a timeline-style visual to contrast established modalities with the emerging TPD field.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/7",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.45,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Timeline from 2010 to 2030",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "443a4396-8335-46fd-b51f-29a9f2ff80ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.45,
        "y": 0.65
      },
      "kind": "list",
      "text": "Elucidation of MOA of thalidomide circa 2010 has profoundly accelerated TPD; Clinical programs with protein degraders have grown exponentially in the past 12 months; This growth will continue in foreseeable future",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3135544-5b34-4e3c-8c69-fd8e12d250ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.57,
        "y": 0.25
      },
      "kind": "table",
      "text": "Targeted Protein Degradation stats: 4 FDA approved, >15 in clinical development",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "075516d2-89e4-4643-b562-2d4ebf224b80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "table",
      "text": "Existing Modalities table showing FDA approved drugs for various modalities",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4afe0286-15c5-42ae-a65e-921316ddf907",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.68,
        "x": 0.16,
        "y": 0.04
      },
      "kind": "title",
      "text": "Exponential Clinical Pipeline Growth of Degraders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16811cc8-a5cc-42ef-a47c-e9948b417690",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "015343d9-f47a-4368-bdcf-f9c3f3e040fe",
      "evidence": "Visual representation of progress from 2010 to 2030",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "e884c680-6f89-46c9-bd8f-2e75036d027c",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The deck presents an overview of proteome editing, Kymera's approach, and key messages, generating interest in the audience.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "7d2f21f7-c191-4e6f-8cc3-d5255feabd13",
      "evidence": "The deck presents a series of slides explaining the problem, complication, and solution, forming a logic chain.",
      "position": 0,
      "objective": "To demonstrate the logic behind Kymera's TPD approach and its potential to expand the druggable proteome.",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}